Daily ergothioneine supplementation for people with kidney failure on dialysis
Repletion of Ergothioneine in Patients With Kidney Failure
This trial tests whether a daily ergothioneine pill can restore blood ergothioneine levels in people with kidney failure who receive dialysis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 28 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Trial ID | NCT06487546 on ClinicalTrials.gov |
What this trial studies
People with kidney failure who receive hemodialysis or peritoneal dialysis will be enrolled and given either a daily ergothioneine supplement or a matching placebo. Blood ergothioneine levels will be measured over the treatment period to see whether supplementation replenishes circulating levels. Participants who recently had a blood transfusion or who already take ergothioneine-containing supplements are excluded. The intervention is administered at a single site in Palo Alto, and safety and tolerability will also be monitored.
Who should consider this trial
Good fit: Adults with kidney failure who are receiving hemodialysis or peritoneal dialysis, not taking ergothioneine supplements, and without a blood transfusion in the prior 90 days are ideal candidates.
Not a fit: People not on dialysis, those already taking ergothioneine supplements, or those who had a blood transfusion within 90 days are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, the supplement could restore ergothioneine levels in dialysis patients, which might help protect cells from oxidative damage and related complications.
How similar studies have performed: Ergothioneine supplementation is a relatively novel approach with limited clinical trial data in dialysis patients, though preclinical and observational studies suggest possible antioxidant benefits.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * kidney failure receiving hemodialysis or peritoneal dialysis Exclusion Criteria: * blood transfusion within 90 days * taking supplements which contain ergothioneine
Where this trial is running
Palo Alto, California
- Veterans Affairs Palo Alto — Palo Alto, California, United States (Recruiting)
Study contacts
- Principal investigator: Tammy Sirich, MD — Stanford University
- Study coordinator: Tammy Sirich, MD
- Email: tsirich@stanford.edu
- Phone: 650-493-5000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.